Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-L1-H

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

PD-L1-H	HER2 Positive Breast Cancer	PD-L1-H	HER2 Positive Breast Cancer	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B
PD-L1-H	Non Small Cell Lung Cancer	PD-L1-H	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
PD-L1-H	Non-Hodgkin’s Lymphoma	PD-L1-H	Non-Hodgkin’s Lymphoma	L/P-VIPD Resistant: C3 – Early Trials L / P-VIPD Resistant : C3	L/P-VIPD Resistant: C3 – Early Trials L / P-VIPD Resistant : C3
PD-L1-H	Urothelial Cancer	PD-L1-H	Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
PD-L1-H	Non Small Cell Lung Cancer	PD-L1-H	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1-H	Bladder Cancer	PD-L1-H	Bladder Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1-H	Neuroendocrine Tumor	PD-L1-H	Neuroendocrine Tumor	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
PD-L1-H	Colorectal Cancer	PD-L1-H	Colorectal Cancer	durvalumab + tremelimumab Resistant: C3 – Early Trials durvalumab + tremelimumab Resistant : C3	durvalumab + tremelimumab Resistant: C3 – Early Trials durvalumab + tremelimumab Resistant : C3
PD-L1-H	Solid Tumor	PD-L1-H	Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1-H	Urothelial Cancer	PD-L1-H	Urothelial Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1-H	Small Cell Lung Cancer	PD-L1-H	Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1-H	Melanoma	PD-L1-H	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1-H	Lung Cancer	PD-L1-H	Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3